AT1
ATOMO DIAGNOSTICS LIMITED
$0.0120
0.00%
Market cap
$11M
Turnover
$25,352
Last price
$0.0120
Day change
0.00%
Announcements
9
Range, past year
Open 0.028 · Low 0.011 · Now 0.012 · High 0.048
Open AT1 in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
AT1 momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
27/100
Wyckoff phase
Downtrend13d
Trend stage
Breakdown
1 Day
+0.0%
1 Week
-14.3%
1 Month
-29.4%
1 Year
-58.6%
RSI
28
Avg daily range
9.6%
ATOMO DIAGNOSTICS LIMITED scores 27 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 13 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
What stands out
- Volume 2.4× 60-day avg
Points to watch
- RSI oversold (28)
- 60d drawdown -36.8%
- High volatility (ATR 9.6%)
- Thin liquidity
- Risk rating: Very High
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsAT1 announcements
Recent price-sensitive releases.
- 2026-10-29 Q1 FY27 Results Presentation Commitments Test Entity - First Quarter Activity Report | Company Presentation
- 2026-10-29 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-10-29 Atomo Signs Agreement with Innovation Scientific Progress Report
- 2026-08-31 2026 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-19 Managing Director & CEO Transition CEO/Managing Director - Appointment Resignation | Director Appointment/Resignation
- 2026-07-23 Quarterly Activities/Appendix 4C Cash Flow Report
- 2026-05-15 Share Purchase Plan Results
More Health Care stocks
Most traded in the same sector.